基因组分析识别新诊断骨髓瘤中的高风险双打击亚组
本研究基于骨髓瘤基因组计划,对1273例新诊断多发性骨髓瘤(NDMM)患者进行全基因组和全外显子分析,识别与无进展生存期(PFS)和总生存期(OS)显著相关的遗传因素。整合DNA驱动因素与临床数据构建Cox模型,并定义了一个高风险亚组:双等位基因TP53失活或CKS1B(1q21)扩增(≥4拷贝)且ISS III期,占人群6.1%,中位PFS 15.4个月,OS 20.7个月,并在独立数据集中验证。
要点
- 全基因组和外显子分析识别与PFS和OS显著相关的遗传因素,累积R²分别为18.4%和25.2%。
- 整合DNA驱动因素与临床数据的Cox模型累积R²为PFS 34.3%和OS 46.5%。
- 高风险亚组定义为双等位基因TP53失活或CKS1B(1q21)扩增(≥4拷贝)且ISS III期,占6.1%,中位PFS 15.4个月,OS 20.7个月。
核心结论
- 通过基因组分析定义了一个高风险双打击亚组,该亚组患者即使接受现代治疗预后仍极差,应考虑新治疗方法。
研究设计与样本
- 基于骨髓瘤基因组计划,对1273例新诊断多发性骨髓瘤患者进行全基因组和全外显子分析;使用784例具有ISS、年龄、PFS、OS和基因组数据的患者构建Cox模型。
主要发现
- 全基因组和外显子数据识别遗传因素对PFS和OS有显著贡献,累积R²分别为18.4%和25.2%。
- 整合DNA驱动因素和临床数据的Cox模型累积R²为PFS 34.3%和OS 46.5%。
- 高风险亚组通过递归分割定义:双等位基因TP53失活或CKS1B(1q21)扩增(≥4拷贝)且ISS III期,占6.1%,中位PFS 15.4个月,OS 20.7个月,并在独立数据集中验证。
关键数值与推荐
- 高风险亚组定义:双等位基因TP53失活或CKS1B(1q21)扩增(≥4拷贝)且ISS III期。
- 高风险亚组占人群6.1%,中位PFS 15.4个月,中位OS 20.7个月。
临床怎么用
- 作者认为双打击患者尽管接受现代治疗预后仍差,应考虑新治疗方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.
引用
- Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2018. PMID: 29967379. doi:10.1038/s41375-018-0196-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。